Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
Identifieur interne : 000220 ( Main/Exploration ); précédent : 000219; suivant : 000221Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
Auteurs : Robert L. Kruse [États-Unis]Source :
- F1000Research [ 2046-1402 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (usage thérapeutique), Anticorps neutralisants (usage thérapeutique), Chine (épidémiologie), Essais cliniques à usage compassionnel, Flambées de maladies, Humains, Infections à coronavirus (traitement médicamenteux), Oligonucléotides (usage thérapeutique), Peptidyl-Dipeptidase A (), Pneumopathie virale (traitement médicamenteux), Repositionnement des médicaments.
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux, Anticorps neutralisants, Oligonucléotides.
- épidémiologie : Chine.
- Essais cliniques à usage compassionnel, Flambées de maladies, Humains, Peptidyl-Dipeptidase A, Repositionnement des médicaments.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Antibodies, Neutralizing (therapeutic use), Betacoronavirus (drug effects), China (epidemiology), Compassionate Use Trials, Coronavirus Infections (drug therapy), Disease Outbreaks, Drug Repositioning, Humans, Oligonucleotides (therapeutic use), Peptidyl-Dipeptidase A (drug effects), Pneumonia, Viral (drug therapy).
- MESH :
- chemical , drug effects : Peptidyl-Dipeptidase A.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Neutralizing, Oligonucleotides.
- geographic , epidemiology : China.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Compassionate Use Trials, Disease Outbreaks, Drug Repositioning, Humans.
Abstract
A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).
DOI: 10.12688/f1000research.22211.2
PubMed: 32117569
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000915
- to stream PubMed, to step Curation: 000915
- to stream PubMed, to step Checkpoint: 000209
- to stream Ncbi, to step Merge: 000C56
- to stream Ncbi, to step Curation: 000C56
- to stream Ncbi, to step Checkpoint: 000C56
- to stream Main, to step Merge: 000222
- to stream Main, to step Curation: 000220
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.</title><author><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287</wicri:regionArea><wicri:noRegion>21287</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32117569</idno><idno type="pmid">32117569</idno><idno type="doi">10.12688/f1000research.22211.2</idno><idno type="wicri:Area/PubMed/Corpus">000915</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000915</idno><idno type="wicri:Area/PubMed/Curation">000915</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000915</idno><idno type="wicri:Area/PubMed/Checkpoint">000209</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000209</idno><idno type="wicri:Area/Ncbi/Merge">000C56</idno><idno type="wicri:Area/Ncbi/Curation">000C56</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C56</idno><idno type="wicri:Area/Main/Merge">000222</idno><idno type="wicri:Area/Main/Curation">000220</idno><idno type="wicri:Area/Main/Exploration">000220</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.</title><author><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287</wicri:regionArea><wicri:noRegion>21287</wicri:noRegion></affiliation></author></analytic><series><title level="j">F1000Research</title><idno type="eISSN">2046-1402</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Neutralizing (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>China (epidemiology)</term><term>Compassionate Use Trials</term><term>Coronavirus Infections (drug therapy)</term><term>Disease Outbreaks</term><term>Drug Repositioning</term><term>Humans</term><term>Oligonucleotides (therapeutic use)</term><term>Peptidyl-Dipeptidase A (drug effects)</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps neutralisants (usage thérapeutique)</term><term>Chine (épidémiologie)</term><term>Essais cliniques à usage compassionnel</term><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Oligonucléotides (usage thérapeutique)</term><term>Peptidyl-Dipeptidase A ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Repositionnement des médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Oligonucleotides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Oligonucléotides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Chine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Compassionate Use Trials</term><term>Disease Outbreaks</term><term>Drug Repositioning</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques à usage compassionnel</term><term>Flambées de maladies</term><term>Humains</term><term>Peptidyl-Dipeptidase A</term><term>Repositionnement des médicaments</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000220 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000220 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32117569
|texte= Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32117569" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |